Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Climb Bio (NASDAQ:CLYM) announced its quarterly earnings data on Tuesday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02, Zacks reports.

Climb Bio Price Performance

Shares of NASDAQ CLYM traded down $0.03 during mid-day trading on Wednesday, reaching $1.27. 87,846 shares of the company’s stock were exchanged, compared to its average volume of 374,537. The stock’s 50-day moving average is $1.59. The firm has a market capitalization of $85.37 million, a price-to-earnings ratio of -0.60 and a beta of -0.19. Climb Bio has a 52-week low of $1.20 and a 52-week high of $11.55.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CLYM shares. Leerink Partnrs raised shares of Climb Bio to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners assumed coverage on shares of Climb Bio in a report on Monday, December 2nd. They issued an “outperform” rating and a $10.00 target price on the stock.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.